A multicenter phase IV clinical trial to examine the change of low-grade side effects after switch to Nilotinib from other tyrosine kinase inhibitors.
Phase of Trial: Phase IV
Latest Information Update: 03 Jun 2014
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 19 May 2014 Status changed from suspended to discontinued as reported by University Hospital Medical Information Network - Japan..
- 27 Jan 2014 Status changed from recruiting to suspended as per University Hospital Medical Information Network - Japan record.
- 04 Oct 2012 New trial record